NYOH patients who need documentation to confirm eligibility to receive the COVID-19 vaccine, visit our COVID-19 resource page to learn how.
Learn More

Clinical Trials & Research

Ph2 T-Vec + Pembro Met Melanoma

(Amgen 20180115) Phase 2 Study of Talimogene Laherparepvec in Combination with Pembrolizumab in Subjects with Unresectable/Metastatic Stage IIIB-IVM1d Melanoma who have Progressed on Prior Anti-PD-1 Based Therapy

Disease Types: Melanoma,&nbs

Available at: {clinical_trial_location backspace="7"}Ph2 T-Vec + Pembro Met Melanoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}